Literature DB >> 7841135

Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.

J K Yao1, D P van Kammen, J Gurklis.   

Abstract

Fatty acid composition was quantitatively analyzed in RBC ghost membranes of 20 schizophrenic patients stabilized with haloperidol (5-20 mg/day) and of the same individuals after haloperdol (HD) withdrawal. The average days on medication and drug-free period were 52 and 40 days, respectively. No significant differences were demonstrated in levels (% or nmol/ml packed RBC) of polyunsaturated fatty acids (PUFAs) between HD-treated and drug-free patients. Similarly, no significant difference was found between relapsed and nonrelapsed schizophrenic patients, although the mean levels of 20:4 (n - 6), total PUFAs or fatty acid unsaturation index (FAUI) were consistently higher in nonrelapsers than in relapsers. On the other hand, the decreases in FAUI were significantly (r = -0.46, p = 0.04) correlated to the increases in psychosis rating which is consistent with our previous reported correlation between altered membrane fluidity and the severity of symptomatology. In addition, decreases in 18:2 (n - 6) but not 20:4 (n - 6) was significantly correlated to the increases in psychosis rating. The present results lend further support that decreased levels of RBC PUFAs in schizophrenic patients lie in an initial stage of PUFAs pathway, possibly a defective uptake of 18:2 (n - 6) into RBC membranes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841135     DOI: 10.1016/0920-9964(94)90046-9

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

Review 1.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  A cytogenetic abnormality and rare coding variants identify ABCA13 as a candidate gene in schizophrenia, bipolar disorder, and depression.

Authors:  Helen M Knight; Benjamin S Pickard; Alan Maclean; Mary P Malloy; Dinesh C Soares; Allan F McRae; Alison Condie; Angela White; William Hawkins; Kevin McGhee; Margaret van Beck; Donald J MacIntyre; John M Starr; Ian J Deary; Peter M Visscher; David J Porteous; Ronald E Cannon; David St Clair; Walter J Muir; Douglas H R Blackwood
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

3.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Ling Yan Qi; Song Chen; Lian Yuan Cao; Da Chun Chen; Mei Hong Xiu; Fan Wang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

4.  Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium.

Authors:  Kristin S Cadenhead; Amedeo Minichino; Skylar Kelsven; Jean Addington; Carrie Bearden; Tyrone D Cannon; Barbara A Cornblatt; Dan Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Jeff Yao
Journal:  Schizophr Res       Date:  2018-09-22       Impact factor: 4.939

5.  A structure-function mechanism for schizophrenia.

Authors:  Kunjumon I Vadakkan
Journal:  Front Psychiatry       Date:  2012-12-28       Impact factor: 4.157

6.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.